Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36306479

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2023 Apr 10
First author
de Castro G Jr

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Transl Lung Cancer Res. 2023 Jul 31;12(7):1636-1642. doi: 10.21037/tlcr-23-245.
    note
    Source null
    related pmid
    37577318
    relationship
    Comment in

Authors and identifiers

  1. name
    de Castro G Jr
    type
    Author
  2. name
    Kudaba I
    type
    Author
  3. name
    Wu YL
    type
    Author
  4. name
    Lopes G
    type
    Author
  5. name
    Kowalski DM
    type
    Author
  6. name
    Turna HZ
    type
    Author
  7. name
    Caglevic C
    type
    Author
  8. name
    Zhang L
    type
    Author
  9. name
    Karaszewska B
    type
    Author
  10. name
    Laktionov KK
    type
    Author
  11. name
    Srimuninnimit V
    type
    Author
  12. name
    Bondarenko I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    de Castro G Jr
    type
    Author
  2. name
    Kudaba I
    type
    Author
  3. name
    Wu YL
    type
    Author
  4. name
    Lopes G
    type
    Author
  5. name
    Kowalski DM
    type
    Author
  6. name
    Turna HZ
    type
    Author
  7. name
    Caglevic C
    type
    Author
  8. name
    Zhang L
    type
    Author
  9. name
    Karaszewska B
    type
    Author
  10. name
    Laktionov KK
    type
    Author
  11. name
    Srimuninnimit V
    type
    Author
  12. name
    Bondarenko I
    type
    Author
bibliography ids
  1. nci-bib-64d25fc245cba5ac53b21a98
book metadata
content sha256
2c89670d912fff0277bab417694b3a33a6d7c0f397be56921175ee57c1500cae
document type
citation
dois
  1. 10.1200/JCO.21.02885
electronic publication date
display
2022 Oct 28
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36306479
immutable id
pubmed:36306479@2c89670d912fff0277bab417694b3a33a6d7c0f397be56921175ee57c1500cae
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
11
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1986-1991
volume
41
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Transl Lung Cancer Res. 2023 Jul 31;12(7):1636-1642. doi: 10.21037/tlcr-23-245.
    note
    Source null
    related pmid
    37577318
    relationship
    Comment in
outcomes validated
false
pmid
36306479
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
2955727c5f23788e2b4131d8162798ffcaf8ba2ef9f2f44bfd91fa15b358b45b
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Apr 10
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Journal Article
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36306479/
title
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Preserved source evidence · Not medical advice